BRCA1 and breast neoplasm: Rottemberg et al. have recently demonstrated in a genetically engineered mouse model of BRCA1 related-breast tumor that the PARP inhibitor AZD2281 (olaparib) is highly effective alone or in combination to CDDP [54].